Portal de Periódicos da CAPES

Drug safety studies and measures of effect using the self‐controlled case series design

2012; Wiley; Volume: 22; Issue: 1 Linguagem: Inglês

10.1002/pds.3337

1099-1557

Kumanan Wilson, Steven Hawken,

Pharmaceutical studies and practices

Pharmacoepidemiology and Drug SafetyVolume 22, Issue 1 p. 108-110 Commentary Drug safety studies and measures of effect using the self-controlled case series design Kumanan Wilson, Corresponding Author Kumanan Wilson +1.613.798.5555 Ext 17921 ICES@Uottawa, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CanadaKumanan Wilson, Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Administrative Services Building, Room 1009, Box 684, Ottawa, ON K1Y 4E9. E–mail: [email protected]Search for more papers by this authorSteven Hawken, Steven Hawken ICES@Uottawa, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CanadaSearch for more papers by this author Kumanan Wilson, Corresponding Author Kumanan Wilson +1.613.798.5555 Ext 17921 ICES@Uottawa, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CanadaKumanan Wilson, Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Administrative Services Building, Room 1009, Box 684, Ottawa, ON K1Y 4E9. E–mail: [email protected]Search for more papers by this authorSteven Hawken, Steven Hawken ICES@Uottawa, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, CanadaSearch for more papers by this author First published: 22 August 2012 https://doi.org/10.1002/pds.3337Citations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25(10): 1768–97. 10.1002/sim.2302 PubMedWeb of Science®Google Scholar 2 Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345(8949): 567–9. 10.1016/S0140-6736(95)90471-9 CASPubMedWeb of Science®Google Scholar 3 Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996; 143(11): 1165–73. 10.1093/oxfordjournals.aje.a008695 CASPubMedWeb of Science®Google Scholar 4 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310(6977): 452–4. 10.1136/bmj.310.6977.452 CASPubMedWeb of Science®Google Scholar 5 Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318(26): 1728–33. 10.1056/NEJM198806303182605 CASPubMedWeb of Science®Google Scholar 6 SEER Stat Fact Sheets: Ovary. National Cancer Institute. U.S. National Institutes of Health. http://seer.cancer.gov/statfacts/html/ovary.html#referencesSEER (accessed December 24, 2011). Google Scholar 7 Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 1998; 339(25): 1797–802. 10.1056/NEJM199812173392501 CASPubMedWeb of Science®Google Scholar 8 Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 156(4): 623–8. Google Scholar 9 Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making 1995; 15(2): 152–7. 10.1177/0272989X9501500208 PubMedWeb of Science®Google Scholar 10 Wilson K, Hawken S, Kwong JC, et al. Adverse Events following 12 and 18 Month Vaccinations: a Population-Based, Self-Controlled Case Series Analysis. PLoS One 2011; 6(12): e27897. 10.1371/journal.pone.0027897 CASPubMedWeb of Science®Google Scholar Citing Literature Volume22, Issue1January 2013Pages 108-110 ReferencesRelatedInformation